Verastem Stops Enrollment In Phase 2 COMMAND Study Of VS-6063

(RTTNews) - Verastem Inc. (VSTM) announced that it has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety Monitoring Board or DSMB review of a pre-planned interim analysis. The results of the analysis demonstrated that VS-6063 had a generally well tolerated safety profile but that there was not a sufficient level of efficacy to warrant continuation of the study.

"We have stopped further enrollment and initiated an orderly wind-down of the COMMAND study," We are disappointed with the COMMAND outcome, but we are deeply grateful for the support and commitment from the patients participating in the study, their families, and the study investigators. Based on these results, we will reevaluate our clinical priorities and direct our resources toward further development of VS-6063, VS-4718, and VS-5584," said Robert Forrester, Verastem President and Chief Executive Officer.

As of the end of the second-quarter 2015, Verastem had $132.1 million in cash and cash equivalents.